Roche’s genomic ambitions
This article was originally published in The Gray Sheet
Executive Summary
Trending of IVD field toward health information could result in "a shuffling of the whole market," approaching a $60 bil.-$80 bil. cap, compared with "$24 bil. for the in vitro market today," Diagnostics Division head Heino von Prondzynski says in annual media conference Feb. 4. "The demarcation lines are going to change. The in vivo...imaging techniques are going to move close together" within the next 10 years, he predicts. "This is the direction in which we as Roche are going to have to go - as a diagnostics company or as a health information company"...